-
Thorac Cancer: ALK positivity is a negative predictor of recurrence-free survival (RFS) in patients with stage I completely resected lung adenocarcinoma
Time of Update: 2022-04-22
Recently, Thoracic Cancer published a study to evaluate the prognostic and predictive significance of ALK positivity in patients with completely resected lung adenocarcinoma .
Recently, Thoracic Cancer published a study to evaluate the prognostic and predictive significance of ALK positivity in patients with completely resected lung adenocarcinoma .
-
J Clin Oncol: Appropriate adjuvant radiotherapy after radical prostatectomy for stage pN1 prostate cancer reduces long-term mortality!
Time of Update: 2022-04-22
For patients with pN1 prostate cancer, appropriate adjuvant radiotherapy after early radical prostatectomy can reduce the risk of subsequent all-cause mortality, and the reduction effect is more significant with the number of positive pelvic lymph nodes .
-
Clin Cancer Res: Fudan Tumor's new therapy for advanced immunomodulatory triple-negative breast cancer (TNBC) with an effective rate of 95.8%
Time of Update: 2022-04-22
In conclusion, the study shows that the triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC .
-
Nature sub-journal: Laser-accelerated proton beam irradiation for tumor therapy
Time of Update: 2022-04-22
The research team constructed a research platform that enables ultra-high peak dose rate irradiation of tumors in small animal models using a proton beam from a laser plasma accelerator .
-
Brit J Cancer: Microbial markers for predicting colorectal tumor risk
Time of Update: 2022-04-22
DigestionThus, this review provides evidence supporting the association between different types of microbial species and their perspective on their predictive value for colorectal tumors .
This review provides evidence supporting the association between different types of microbial species and their predictive value for colorectal tumors .
-
Clin Cancer Res: A biomarker that predicts response to treatment with sintilimab combined with IBI305 in advanced hepatocellular carcinoma!
Time of Update: 2022-04-22
Sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab are antiangiogenic drugs in the standard systemic treatment of advanced hepatocellular carcinoma, but the median overall survival is only 10.
-
BMC Cancer: The Zhongzhun team has a remarkable curative effect on the transformation model therapy for HER2-positive refractory metastatic breast cancer
Time of Update: 2022-04-22
The study included patients with rapidly progressive HER2-positive metastatic breast cancer treated with trastuzumab in 6 hospitals in China who switched to oral lapatinib 1250 mg qd + capecitabine (1000 mg/m2 bid d1-d14 per day) or vinorelbine Bing (25 mg/m2/time, intravenous injection, d1 and d8, every 21 days as a cycle) .
-
11,100 people are diagnosed with cancer every day!
Time of Update: 2022-04-22
(A) Cancer incidence and new cases by sex and age; (B) Cancer mortality by age and mortality by sex Lung, liver, stomach, colorectal, and esophageal cancers were the five causes of cancer deaths, accounting for 69.
-
JAMA sub-issue: More than 90% of cancer patients develop antibodies after COVID-19 vaccination!
Time of Update: 2022-04-22
Taken together, the results of this cohort study suggest that patients with solid tumors or hematological tumors develop an immune response following the COVID-19 vaccine, albeit at lower levels of antibodies than adults without cancer .
-
European Radiology: The value of DW MRI in predicting early response to neoadjuvant chemotherapy in breast cancer
Time of Update: 2022-04-22
Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements .
1007/s00330- 021-08462-zNathalie A Hottat Dominique A Badr Sophie Lecomte ,et al Value of diffusion-weighted MRI in predicting early response to neoadjuvant chemotherapy of breast cancer: comparison between ROI-ADC and whole-lesion-ADC measurements 10.
-
[Nature sub-issue] Designing a "stealth coat" for bacteria to deliver drugs to tumors and kill cancer cells!
Time of Update: 2022-04-22
Bacterial cancer therapy has unique advantages over conventional drug therapy!Columbia University School of Engineering researchers report they have developed a "stealth" system that temporarily hides therapeutic bacteria from the immune system, allowing them to more efficiently deliver drugs to tumors that kill mice of cancer cells .
-
Clin Cancer Res: Nivolumab significantly prolongs long-term survival in advanced esophageal squamous cell carcinoma
Time of Update: 2022-04-22
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3 )
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3 )
-
J Immunother Cancer: The efficacy of nivolumab (nivolumab) combined with cabozantinib (cabozantinib) in patients with advanced endometrial cancer
Time of Update: 2022-04-22
immune blood vesselsThe researchers randomized patients with recurrent endometrial cancer in a 2:1 ratio to nivolumab in combination with cabozantinib (arm A) and nivolumab alone (arm B), with the primary endpoint being progression-free survival (PFS) .
-
Mol Cancer: Novel biomarker SNORD33 predicts sensitivity to platinum-based chemotherapy in triple-negative breast cancer
Time of Update: 2022-04-22
Researcher Chen Yu from School of Basic Medicine, Fudan University, Professor Wang Biyun from Affiliated Cancer Hospital, and Professor Fu Chaowei from School of Public Health collaborated to discover the predictive effect of plasma small nucleolar RNA SNORD33 on platinum sensitivity in triple-negative breast cancer patients, and revealed methyl The protein binding protein MeCP2 is involved in the molecular mechanism of platinum resistance regulated by SNORD33 .
-
Eur J Cancer: Real clinical efficacy of MEK inhibitors in NRAS-mutant metastatic melanoma
Time of Update: 2022-04-22
MEK inhibitors (MEKi) have shown clinical efficacy in NRAS-mutated metastatic melanoma in randomized controlled trials, but their clinical use is currently limited to advanced, pretreated patients, in contrast to previous trials.
-
Int J Cancer: Does the number of pigmented moles correlate with cancer risk?
Time of Update: 2022-04-22
Any cancer excludes skin cancer; blood diseases includes leukemia and lymphoma; head and neck excludes lip cancer; basal cell carcinoma; squamous cell carcinoma, squamous cell carcinoma of the skinFigure 2 Association of genetically predicted mole counts with individual or overall cancer risk according to mole count quartile polygenic risk score (PRS) using individual-level data from the QSkin cohort .
-
Clin Cancer Res: bimetinib combined with ribocillin for NRAS-mutated melanoma
Time of Update: 2022-04-22
In conclusion, the combination regimen of bimetinib and ribocillin can be safely used in NRAS-mutated melanoma patients with positive therapeutic activity .
The combination regimen of bimetinib and ribocillin can be safely used in patients with NRAS-mutated melanoma and has positive therapeutic activity .
-
Transl Lung Cancer Res: Safety and efficacy of nivolumab combined with recombinant human endostatin in the treatment of previously treated advanced non-small cell lung cancer
Time of Update: 2022-04-22
Recently, a team from the Fifth Affiliated Hospital of Sun Yat-Sen University conducted a related study to evaluate the safety and efficacy of nivolumab (nivolumab) combined with recombinant human endostatin in previously treated advanced non-small cell lung cancer (NSCLC) .
-
Lancet Oncol: Lucaparib as an Alternative to Chemotherapy for BRCA1/2 Mutant Recurrent Ovarian Cancer
Time of Update: 2022-04-22
The aim of this study was to evaluate the efficacy of the PARP inhibitor lucaparib versus platinum-based and non-platinum-based chemotherapy in BRCA1/2-mutated ovarian cancer .
In the efficacy analysis population (220 in the rucaparib group and 105 in the chemotherapy group), the median progression-free survival was 7.
-
J Clin Oncol: Domestic multicenter phase III study shows that preoperative short-course radiotherapy + chemotherapy (TNT) is a feasible treatment option for locally advanced rectal cancer
Time of Update: 2022-04-22
Patients were randomly assigned (1:1) to short-term radiotherapy (25 Gy, divided into 5 sessions over 1 week) followed by 4 cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiation (50 Gy, divided into 25 sessions over 5 sessions) Weeks, concurrent use of capecitabine [chemochemotherapy; CRT]) .
